Logo image of NEUE

NEUEHEALTH INC (NEUE) Stock Fundamental Analysis

NYSE:NEUE - New York Stock Exchange, Inc. - US10920V4041 - Common Stock - Currency: USD

6.8  +0.07 (+1.04%)

Fundamental Rating

1

Taking everything into account, NEUE scores 1 out of 10 in our fundamental rating. NEUE was compared to 105 industry peers in the Health Care Providers & Services industry. NEUE has a bad profitability rating. Also its financial health evaluation is rather negative. NEUE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NEUE had negative earnings in the past year.
In the past year NEUE has reported a negative cash flow from operations.
NEUE had negative earnings in each of the past 5 years.
In multiple years NEUE reported negative operating cash flow during the last 5 years.
NEUE Yearly Net Income VS EBIT VS OCF VS FCFNEUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

With a Return On Assets value of -110.18%, NEUE is not doing good in the industry: 94.29% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -110.18%
ROE N/A
ROIC N/A
ROA(3y)-54.32%
ROA(5y)-38.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUE Yearly ROA, ROE, ROICNEUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NEUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUE Yearly Profit, Operating, Gross MarginsNEUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

3

2. Health

2.1 Basic Checks

NEUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEUE has been increased compared to 1 year ago.
NEUE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NEUE is higher compared to a year ago.
NEUE Yearly Shares OutstandingNEUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
NEUE Yearly Total Debt VS Total AssetsNEUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of -5.78, we must say that NEUE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.78, NEUE is doing worse than 87.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.78
ROIC/WACCN/A
WACC9.58%
NEUE Yearly LT Debt VS Equity VS FCFNEUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B

2.3 Liquidity

A Current Ratio of 3.45 indicates that NEUE has no problem at all paying its short term obligations.
NEUE's Current ratio of 3.45 is amongst the best of the industry. NEUE outperforms 89.52% of its industry peers.
NEUE has a Quick Ratio of 3.45. This indicates that NEUE is financially healthy and has no problem in meeting its short term obligations.
NEUE has a Quick ratio of 3.45. This is amongst the best in the industry. NEUE outperforms 90.48% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
NEUE Yearly Current Assets VS Current LiabilitesNEUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

2

3. Growth

3.1 Past

NEUE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -188.05%.
EPS 1Y (TTM)-188.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.57%

3.2 Future

NEUE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.62% yearly.
NEUE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.81% yearly.
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

NEUE Yearly Revenue VS EstimatesNEUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
NEUE Yearly EPS VS EstimatesNEUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NEUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NEUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEUE Price Earnings VS Forward Price EarningsNEUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUE Per share dataNEUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 -200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.62%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NEUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUEHEALTH INC

NYSE:NEUE (4/25/2025, 8:26:25 PM)

6.8

+0.07 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-20 2025-03-20/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners55.18%
Inst Owner ChangeN/A
Ins Owners7.44%
Ins Owner Change43.07%
Market Cap58.82M
Analysts45
Price Target7.14 (5%)
Short Float %0.17%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-79.05%
Min EPS beat(2)-118.63%
Max EPS beat(2)-39.47%
EPS beat(4)1
Avg EPS beat(4)80.65%
Min EPS beat(4)-118.63%
Max EPS beat(4)572.52%
EPS beat(8)3
Avg EPS beat(8)33.15%
EPS beat(12)3
Avg EPS beat(12)-17.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.78%
Min Revenue beat(2)-12.25%
Max Revenue beat(2)-3.31%
Revenue beat(4)1
Avg Revenue beat(4)-5.35%
Min Revenue beat(4)-12.25%
Max Revenue beat(4)1.3%
Revenue beat(8)2
Avg Revenue beat(8)-13.77%
Revenue beat(12)2
Avg Revenue beat(12)-44.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-64.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-38.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.76
EYN/A
EPS(NY)-16.99
Fwd EYN/A
FCF(TTM)-240.59
FCFYN/A
OCF(TTM)-240.43
OCFYN/A
SpS119.46
BVpS-44.67
TBVpS-53.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.32%
ROA(5y)-38.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.22%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -5.78
F-Score2
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)50.59%
Cap/Depr(5y)60.56%
Cap/Sales(3y)1.13%
Cap/Sales(5y)0.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-188.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.14%
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.57%
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.59%
EBIT Next 3Y28.4%
EBIT Next 5YN/A
FCF growth 1Y-852.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-767.21%
OCF growth 3YN/A
OCF growth 5YN/A